MedTrace Logo

Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy

NCT03322969 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-26

No results posted yet for this study

Summary

For patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of \<50% as the criterion of treatment change. Sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy.

Conditions

  • Locally Advanced Gastric Cancer

Interventions

DRUG

Paclitaxel/DDP

receiving the modified chemotherapy

DRUG

XELOX/SOX

receiving the original chemotherapy

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Lin Zhao, Doctor · Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-23
Primary Completion
2022-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322969 on ClinicalTrials.gov